01 — Evidence
Evidence Summary
Genistein has a genuine completed-trial record in oncology — and none of it shows a tumor benefit. The completed human trials are null (no PSA change on a high-dose soy extract; a borderline, non-significant prostate signal) or actively concerning (a randomized breast-cancer trial found a pro-proliferative gene signature). A broad, separate preclinical case sits underneath, qualified throughout by a large gap between the concentrations active in the laboratory and the free genistein that oral dosing actually reaches.
Human
Clinical Record
Completed oncology trials; no tumor benefit
Genistein has completed oncology trials, and none demonstrates a tumor benefit — the results are null or point the wrong way.
- A metastatic colorectal-cancer pilot added genistein to chemotherapy safely, but was uncontrolled and cannot show added benefit
- Two prostate trials — one before surgery, one during active surveillance — found no clear PSA benefit and no change in tumor proliferation
- A randomized breast-cancer trial found soy supplementation raised proliferation-gene expression in tumor tissue in some women
Animal
Preclinical Signal
Multiple tumor models; a promotion signal
Genistein on its own suppressed tumors across several cancer types in vivo — but the animal record is not uniformly favorable.
- Reduced tumor growth or metastasis in esophageal, pancreatic, colorectal, prostate, liver, head-and-neck and melanoma models
- In an advanced prostate model, genistein instead increased metastasis and growth-factor signaling
- In estrogen-driven breast models, genistein enlarged tumors and negated tamoxifen
In Vitro
Cell Model Data
Broad mechanism panel; concentration-dependent
Genistein's most distinctive laboratory finding is epigenetic — it reactivates silenced tumor-suppressor genes — alongside anti-glycolytic, pro-apoptotic and cell-cycle effects.
- Inhibited DNA methyltransferase 1, reactivating silenced tumor-suppressor genes
- Suppressed STAT3, PI3K/Akt and Wnt signaling, and triggered apoptosis and ferroptosis
- Effective concentrations sit well above the free genistein that oral dosing reaches
Human
Clinical Record
No completed genistein oncology trial has shown a tumor benefit; the record is null in prostate cancer and points the wrong way in breast. In a phase I/II pilot in metastatic colorectal cancer, genistein added to FOLFOX or FOLFOX-bevacizumab in 13 newly-diagnosed patients was reported safe and tolerable with no increase in chemotherapy-related adverse events — but the study was uncontrolled and single-arm, so its response rate cannot be read as added benefit.[1]
Continue reading — full research detail+
In localized prostate cancer, a randomized, placebo-controlled trial gave 30 mg/day synthetic genistein for 3–6 weeks before prostatectomy. Serum PSA fell 7.8% on genistein versus a 4.4% rise on placebo — a borderline, non-significant difference (P=0.051) — and the matched tumor-tissue analysis found no significant effect on proliferation (Ki-67), cell-cycle, apoptosis or neuroendocrine markers, only a reduction in KLK4 messenger RNA.[2,3] A separate double-blind trial of a high-dose, aglycone-rich soy extract (450 mg/day genistein) in men on active surveillance found no PSA change at 6 or 12 months, despite serum genistein reaching about 40 µmol/L.[4] A harder endpoint tells the same story: a randomized trial of soy protein isolate for two years after prostatectomy was stopped for futility, with no reduction in biochemical recurrence (hazard ratio 0.96).[65]
The most important human signal points away from benefit. A randomized trial in 140 women with breast cancer, dosed from diagnosis to surgery, reported that soy supplementation was associated with over-expression of cell-cycle and proliferation genes (including FGFR2, CCNB2, MYBL2 and CDK1) in tumor tissue in the high-genistein subset, leading the authors to warn that soy could adversely affect gene expression in some women.[5] A separate six-month randomized prevention trial of mixed soy isoflavones in high-risk women pointed the same way — no reduction in breast-tissue proliferation, and a rise in Ki-67 among premenopausal participants.[64] Human pharmacokinetic work underlies the whole picture: in cancer patients dosed with soy isoflavones, total plasma genistein reached the low-micromolar range but the free, active aglycone stayed at roughly one to four percent of that, the rest circulating as largely inactive conjugates.[7] A completed pancreatic-cancer trial that added a soy-isoflavone concentrate to gemcitabine and erlotinib found the combination feasible but did not improve survival.[51]
Signal maturity: a genuine completed-trial record — larger than for most dietary compounds — whose results are null in prostate and unfavorable in breast. The registered landscape (roughly 32 genistein oncology trials) clusters in prostate, breast, bladder and pancreatic cancer, with several trials terminated or withdrawn for non-accrual.[52] No trial has shown that genistein shrinks a tumor or improves survival.
Animal
Preclinical Signal
Genistein on its own suppressed tumors across several cancer types in vivo, but the animal record is genuinely two-directional. On the favorable side, it reduced tumor growth or metastasis in esophageal, pancreatic, colorectal, prostate, hepatocellular, head-and-neck and melanoma models.[53,8,13,11,15,55,56]
Continue reading — full research detail+
The clearest in-vivo signal from genistein alone is esophageal: oral genistein (5–10 mg/kg) dose-dependently suppressed a xenograft while sparing normal esophageal cells, with reduced EGFR and downstream cell-cycle and apoptosis changes confirmed in tumor tissue.[53] Genistein also reduced angiogenesis and growth in a pancreatic orthotopic model,[8] suppressed prostate cancer-stem-cell tumorigenicity,[11] reduced colorectal liver metastasis,[13] blocked carcinogen-induced pre-neoplasia in rat colon,[19] suppressed an oral-dosed hepatocellular xenograft by lowering glucose metabolism,[15] and reduced head-and-neck and gastric tumor growth via cancer-stem-cell suppression.[55,60] In an ovarian xenograft it acted anti-estrogenically, reversing the estrogen-driven crosstalk that fueled tumor growth.[54]
Against this sits the single most important animal finding here: in a patient-derived model of advanced prostate cancer, both low and high doses of pure genistein increased lymph-node and distant metastasis, raised proliferation and EGFR/Src signaling, and lowered apoptosis.[25] The dietary breast-cancer models are also consistently unfavorable — genistein enlarged estrogen-receptor-positive tumors in ovariectomized mice and negated tamoxifen.[41,42,43]
Signal maturity: multi-cancer preclinical activity that is real but not uniformly beneficial. The effect of genistein on EGFR signaling is genuinely bidirectional in vivo — suppressed in esophageal tumor tissue, increased in advanced prostate — and the estrogen-driven breast and prostate models show outright tumor promotion, so the animal case cannot be read as uniformly anti-cancer.
In Vitro
Cell Model Data
Genistein's most distinctive laboratory mechanism is epigenetic: it has been reported to inhibit DNA methyltransferase 1 and reactivate silenced tumor-suppressor genes, alongside anti-glycolytic, pro-apoptotic, cell-cycle and ferroptosis effects across prostate, breast, colorectal, pancreatic, bladder, renal, hepatocellular and leukaemia lines.
Continue reading — full research detail+
In breast cancer cells, genistein was reported to lower DNA methyltransferase 1 (but not the DNMT3 isoforms), demethylating and reactivating the tumor-suppressor genes ATM, APC, PTEN and SERPINB5, with molecular modelling predicting an interaction with the enzyme's catalytic domain.[16] It shifted histone marks toward a transcriptionally active state at cancer genes at 18.5 µM,[18] suppressed STAT3 and its survival targets with tumor-selective potency in pancreatic cells (IC50 20–25 µM versus 120 µM in non-cancerous ductal cells),[20] and induced iron-dependent ferroptosis in colorectal cells via the FoxO3/SLC7A11/GPX4 axis (IC50 108–113 µM).[30]
The exposure gap is the qualifier on every one of these findings. Genistein's effective concentrations cluster at roughly 5 to 113 µM, while the free (unconjugated) genistein achievable in human plasma sits near 0.07–0.17 µM[7] — a gap of two to three orders of magnitude for the cytotoxic mechanisms. Genistein's dose–response also runs both ways: at the low, achievable concentrations it can act as an estrogen agonist and stimulate estrogen-receptor-positive growth, only becoming antiproliferative above about 20 µM.[41]
Signal maturity: the DNA-methyltransferase / epigenetic mechanism is the deepest and most distinctive cell-model finding for genistein, and several mechanisms carry animal corroboration. The persistent limitation is that the concentrations driving these effects are far above the free genistein oral dosing reaches, and the same low-concentration range is where the estrogenic, growth-stimulatory direction appears.
Advertisement
02 — Pathways
Pathway Interaction Profile
Genistein engages several distinct biological pathways relevant to tumor behavior, grouped below by the functional role each one supports. This includes direct anti-tumor mechanisms and, further down, a separate set of pathways supporting the body's own resilience. Two qualifiers run through all of them: the concentrations that drive these effects sit well above what oral dosing reaches as free genistein, and — for the growth-factor and hormone pathways — genistein's direction of effect can reverse.
Genistein's Contain classification rests on reported suppression of tumor blood-vessel growth, the invasion machinery that lets cancer cells break away from a lesion, and the cancer-stem-cell traits that seed new sites — corroborated beyond cell studies in several animal models, but held to partial by a large gap between the effective and the orally achievable concentrations, and by one model where an anti-angiogenic marker change did not translate into slower tumor growth.
Block Seeding & Niche Formation
Research concerning formation of supportive pre-metastatic niches at distant sites.
Angiogenesis / VEGF / HIF-1α
Genistein has been reported to block HIF-1 activation and lower VEGF, reducing tumor angiogenesis and growth in a pancreatic orthotopic model, and to disrupt VEGF-stimulated endothelial-cell activation by lowering endothelial tyrosine-kinase activity and MMP production.[8,10] A B16 melanoma model adds breadth, with reduced tumor volume and no liver metastasis, though from a single lower-tier study.[56] One honest counterpoint: in an oral-squamous-carcinoma model genistein reduced microvessel density but did not significantly change tumor growth or metastasis, so a marker effect did not become an outcome.[9]
NF-κB / TNF-α / IL-6 inflammatory axis
In bladder cancer, genistein has been reported to counteract chemotherapy-induced activation of the anti-apoptotic NF-κB pathway, sensitizing cells to the topoisomerase-I inhibitor hydroxycamptothecin through synergistic ATM activation and DNA damage, with corroboration in a xenograft.[14] This is a genistein–chemotherapy combination rather than genistein suppressing NF-κB on its own, so it is carried as a chemosensitizer finding.
Prevent Tumor Cell Shedding
Research concerning invasion and escape from existing lesions (EMT and ECM breach).
EMT & metastatic invasion
In colorectal cancer cells, genistein has been reported to demethylate the Wnt-inhibitor gene WIF1, restoring its expression and reducing invasion and migration with lower MMP-2/9 and higher E-cadherin; WIF1 knockdown reversed the effect.[12] This invasion signal carries an in-vivo anchor: genistein lowered KCNK9, attenuated Wnt/β-catenin, and reduced the number and size of liver metastases in a colorectal model,[13] and it repressed epithelial-mesenchymal transition in head-and-neck tumor-initiating cells.[55] The same growth-factor machinery reverses in advanced prostate — see the EGFR/HER card under Weaken.
Prevent Dormant Reactivation
Research concerning wake-up signalling and reactivation of dormant disseminated tumour cells.
Cancer stemness (CD44, ALDH, Nanog/Sox2)
Genistein has been reported to suppress cancer-stem-cell traits across three cancers, with in-vivo corroboration each time: reduced tumorsphere formation, lower CD44, and Hedgehog-Gli1 suppression with reduced tumorigenicity in prostate;[11] a lower ALDH1+/CD44+ fraction and repressed self-renewal through miR-34a in head-and-neck cells;[55] and reduced self-renewal, lower drug-efflux ABCG2, and smaller xenograft mass in gastric cancer.[60] Effective concentrations were not tied to orally achievable free plasma levels, and the gastric xenograft used a low intraperitoneal dose.
Genistein's Starve classification rests on a single but unusually direct piece of evidence: suppression of tumor glucose metabolism through a functionally validated, HIF-1α-dependent mechanism, corroborated by oral dosing in an animal model — but at concentrations well above what oral dosing achieves as free genistein.
Glucose Axis Pressure
Research concerning glycolytic ATP production and glycolytic intermediates used by cancer cells.
Aerobic glycolysis (Warburg effect)
In hepatocellular carcinoma, genistein has been reported to lower HIF-1α by roughly 84% — a functionally confirmed dependence, since the anti-glycolytic effect was abolished in HIF-1α-silenced cells and restored by a HIF stabilizer — and to down-regulate GLUT1 and hexokinase-2, cutting glucose uptake and lactate by about half; dissociation of hexokinase-2 from mitochondrial VDAC triggered apoptosis, and oral genistein (40–80 mg/kg) suppressed the xenograft.[15] The tumor-cell IC50 (67–104 µM) sits far above achievable free plasma exposure, with only a modest selectivity margin over a normal-liver line.
Genistein's Weaken classification is the best-populated tumor-directed role, built on its most distinctive mechanism — epigenetic reactivation of silenced tumor-suppressor genes — plus STAT3, PI3K/Akt, Wnt and cell-cycle suppression, several with animal corroboration. It is held to partial by the concentration gap and by a genuinely bidirectional growth-factor arm: genistein suppressed EGFR in esophageal tumor tissue yet increased it, and promoted metastasis, in advanced prostate.
Expansion Suppression
Research concerning proliferation, cell-cycle progression, and the capacity of lesions to add durable mass.
PI3K–AKT–mTOR
The role's clearest in-vivo anchor sits here: in esophageal carcinoma, genistein has been reported to suppress the Akt/MDM2/p53 arm downstream of EGFR (the phospho-cascade shown in cells), with EGFR down-regulation, G0/G1 arrest and apoptosis confirmed in tumor tissue and dose-dependent xenograft inhibition.[53] In bladder cells it inactivated PI3K/Akt in a ROS-dependent manner;[21] in an ovarian xenograft it lowered pIRS-1 and pAkt by reversing estrogen-receptor–IGF-1R crosstalk;[54] and a genistein-combined-polysaccharide preparation suppressed mTOR-p70S6K and androgen-receptor signaling in prostate cells.[22] The prostate data used a genistein-containing mixture, and the ovarian effect is contingent on an estrogen-driven model.
JAK/STAT (STAT3)
Genistein's STAT3 suppression has an in-vivo anchor from genistein alone: in esophageal carcinoma it reduced EGFR and phospho-JAK1/2, blocking STAT3 phosphorylation and nuclear translocation, with tumor-selective potency (IC50 5–15 µM in three esophageal lines versus 125 µM in normal esophageal epithelium) and a matched xenograft confirming EGFR down-regulation in tissue.[53] In pancreatic cancer cells it suppressed STAT3 and its survival targets (survivin, cyclin D1, ALDH1A1) with G0/G1 arrest and apoptosis, again tumor-selective (IC50 20–25 µM versus 120 µM in normal ductal cells).[20]
Wnt / β-catenin
Genistein has been reported to block Wnt signaling by two routes, one corroborated in vivo. In a carcinogen-induced (azoxymethane) rat colon model, dietary genistein blocked nuclear β-catenin accumulation, lowered cyclin D1 and c-Myc, and reduced aberrant crypt foci;[19] in colorectal cells it demethylated WIF1 to restore Wnt inhibition[12] and lowered KCNK9 to suppress liver metastasis in vivo.[13] Animal-corroborated in a prevention setting.
Cell cycle checkpoints (CDK4/6–RB–E2F, G1/S, G2/M)
Genistein has been reported to arrest the cell cycle across several lines, at different checkpoints: G2/M arrest with lowered cyclins A/B1 and raised p21 in bladder cells,[21] G0/G1 arrest with lowered cyclin D1/CDK4/6 in pancreatic and esophageal cells (the esophageal arrest corroborated in tumor tissue),[20,53] and CDK4/p21-mediated G2/M arrest in colon cells with soy isoflavones.[27] A human observational dataset points the same way — higher serum genistein was associated with lower odds of high Ki-67 in 1,060 breast-cancer patients.[23]
EGFR / HER-family signaling — bidirectional in vivo
Genistein's effect on this axis runs both ways depending on tissue, and it is the page's clearest direction hazard. In its favor: it suppressed HER2 protein and phosphorylation in breast cells independent of ERα,[24] enhanced trastuzumab's effect in HER2-positive cells,[26] and — an in-vivo suppression signal — down-regulated EGFR directly in esophageal tumor tissue.[53] But in a patient-derived model of advanced human prostate cancer, pure genistein did the opposite: it raised EGFR (Y1068) and Src (Y416) phosphorylation, increased proliferation, lowered apoptosis, and promoted lymph-node and distant metastasis at both low and high doses.[25] The one human tumor-tissue readout sits on the suppressive side: in a randomized presurgical trial in bladder cancer, oral genistein (as the soy extract G-2535) lowered tumor EGFR phosphorylation at 300 mg/day (P=0.015), though the 600 mg dose did not reproduce it and other markers were unchanged.[62] The growth-factor arm cannot be read as uniformly suppressive.
Metabolic Weakening
Research concerning tumour metabolic competence and adaptive capacity over time.
Epigenetic regulation & transcriptional control
Genistein's most distinctive mechanism class, and comparatively well developed in cell models. It has been reported to lower DNA methyltransferase 1 (but not the DNMT3 isoforms), demethylating and reactivating the tumor-suppressor genes ATM, APC, PTEN and SERPINB5 in breast cells, with modelling predicting a catalytic-domain interaction;[16] to demethylate the BTG3 promoter and add activating histone marks in renal cancer, comparable to the drug 5-aza-2′-deoxycytidine;[17] and to shift histone marks toward an active state at cancer genes at 18.5 µM.[18] A related transcriptional route is microRNA: genistein up-regulated the tumor-suppressor miR-34a to reduce stemness in head-and-neck cells in vitro and in vivo.[55]
Genistein's Attack classification rests on intrinsic (mitochondrial) apoptosis with in-vivo corroboration from genistein alone, plus a recent ferroptosis mechanism. It is held to partial by the roughly 100-micromolar effective concentrations and by the fact that its oldest killing mechanism — topoisomerase-II poisoning — is genotoxic and double-edged, so it is carried below as exploratory rather than as a clean Attack pathway.
Direct Tumor-Directed Killing
Research concerning regulated tumour-cell death (apoptosis, ferroptosis, necroptosis).
Intrinsic apoptosis (mitochondrial / Bcl-2)
Genistein has been reported to raise the Bax/Bcl-2 ratio, activate caspase-9/-3, dissipate mitochondrial membrane potential and increase ROS across tumor lines, with in-vivo corroboration from genistein alone: an oral esophageal xenograft showed in-tumor Bax/PARP/caspase-3 changes,[53] and a leukaemia (HL-60) xenograft reduced tumor weight, albeit at an unusually low intraperitoneal dose.[28] A neuroblastoma study reproduced the mitochondrial route but used a genistein plus fenretinide combination in vivo.[29]
Ferroptosis (execution / cell death)
In colorectal cancer cells, genistein has been reported to induce iron-dependent ferroptosis via the FoxO3/SLC7A11/GPX4 axis — raising iron, malondialdehyde and ROS and lowering SLC7A11 and GPX4, with both ferrostatin-1 and GPX4 over-expression rescuing the cells (IC50 108–113 µM).[30] This is in-vitro, at high micromolar concentrations, and pro-oxidant in direction — the opposite of genistein's antioxidant activity elsewhere — so it is a genuine but context-dependent lever.
Genistein's Protect classification covers two kinds of evidence. One is human tolerability data from its cancer trials — genistein was safely combined with chemotherapy, though without a demonstrated host benefit. The other is a distinctive, mechanistically selective preclinical radioprotection story, set out below, backed by strong animal data but not yet by controlled human host-outcome evidence.
Oncology Host-Status
Tolerability in a chemotherapy combination — in the metastatic-colorectal-cancer pilot, adding genistein to FOLFOX or FOLFOX-bevacizumab did not increase chemotherapy-related adverse events and was judged safe and tolerable.[1] This is a tolerability observation in an uncontrolled 13-patient study, not a demonstrated reduction in toxicity; a pancreatic gemcitabine/erlotinib combination likewise found genistein feasible to add but without a survival benefit.[51]
Other Organ-System Reserve
Research concerning renal, cardiac, pulmonary, and other non-hepatic organ reserve under stress.
Radiation protection of normal tissue — the selective, dual-benefit case
Genistein's strongest and most-developed host-protection story is radioprotection, and it is mechanistically selective. The best-characterized effect is hematopoietic: a single subcutaneous dose (200 mg/kg, 24 hours before 8.75 Gy total-body irradiation) raised 30-day survival to 97% versus 31% in vehicle and 0% untreated mice, by accelerating bone-marrow progenitor recovery.[57] This is the effect the clinical-stage nanosuspension BIO 300 was built on, under development as a pre-exposure radiation countermeasure for hematopoietic-acute-radiation-syndrome.[58] The same platform also reduced radiation injury to normal lung, cutting pulmonary-fibrosis incidence and severity.[36,37] This has now been carried into humans: in an open-label early-phase study, lung-cancer patients given oral BIO 300 during chemoradiotherapy showed a dose-dependent fall in the fibrosis marker TGF-β1 with no dose-limiting toxicity — but the study was uncontrolled, so it cannot yet demonstrate a normal-tissue-protection benefit attributable to genistein.[61] Separately, genistein radiosensitized prostate tumor cells, enhancing radiation's effect while driving G2/M arrest and apoptosis.[39,40]
A striking mechanistic twist ties this benefit to the page's central hazard: BIO 300's radioprotection appears estrogen-receptor-mediated — a broad estrogen-receptor antagonist abolished the survival benefit, consistent with genistein's preferred ERβ activity — so it draws on the same estrogen-receptor pharmacology behind the tamoxifen-antagonism concern. The two are related rather than identical, though: the low-dose breast-proliferation hazard is thought to run largely through ERα, while this protection tracks ERβ.[58] The normal-tissue protection is preclinical, several key results use the nanosuspension formulation or a subcutaneous route, and the same research lineage separately reported that dietary genistein can promote metastasis,[25] so the selectivity holds for the radiation setting specifically, not for genistein use in general.
Other Organ-System Reserve
Research concerning renal, cardiac, pulmonary, and other non-hepatic organ reserve under stress.
Chemotherapy organ protection (cardiac and renal)
In mice, genistein has been reported to reduce doxorubicin-induced cardiac injury, oxidative stress and inflammatory cytokines via the Nrf2/HO-1/NQO1 axis,[38] and to protect the kidney from cisplatin injury (mouse and human cells) by lowering ROS, NF-κB activation and p53-dependent apoptosis.[59] Both work through the same antioxidant and NF-κB axes tumors use to resist oxidative and platinum therapy, and neither was tested in a tumor-bearing model, so treatment selectivity is unestablished; preclinical only.
Block Seeding & Niche Formation
Research concerning formation of supportive pre-metastatic niches at distant sites.
Genistein has been reported to lower VEGF and block HIF-1 activation, reducing tumor blood-vessel growth in animal models — though in one model the marker change did not slow tumor growth.
Prevent Dormant Reactivation
Research concerning wake-up signalling and reactivation of dormant disseminated tumour cells.
Cancer stemness (CD44, ALDH, Nanog/Sox2)
Genistein has been reported to suppress cancer-stem-cell traits with in-vivo corroboration in prostate, head-and-neck and gastric models.
Glucose Axis Pressure
Research concerning glycolytic ATP production and glycolytic intermediates used by cancer cells.
Aerobic glycolysis (Warburg effect)
Genistein has been reported to lower HIF-1α and shut down glucose metabolism in liver-cancer cells, with an oral-dosed animal model — at concentrations above what oral dosing reaches.
Metabolic Weakening
Research concerning tumour metabolic competence and adaptive capacity over time.
Epigenetic regulation & transcriptional control
Genistein's most distinctive mechanism: it has been reported to inhibit DNA methyltransferase 1 and switch silenced tumor-suppressor genes back on in cell studies.
Expansion Suppression
Research concerning proliferation, cell-cycle progression, and the capacity of lesions to add durable mass.
Genistein has been reported to block STAT3 signaling with tumor-selective potency and an animal anchor from genistein alone in esophageal cancer.
Direct Tumor-Directed Killing
Research concerning regulated tumour-cell death (apoptosis, ferroptosis, necroptosis).
Intrinsic apoptosis (mitochondrial / Bcl-2)
Genistein has been reported to trigger mitochondrial apoptosis, with animal corroboration from genistein alone in esophageal and leukaemia models.
Other Organ-System Reserve
Research concerning renal, cardiac, pulmonary, and other non-hepatic organ reserve under stress.
Radiation protection of normal tissue
Genistein has been reported to protect normal bone marrow and lung from radiation while radiosensitizing tumor cells — a selective, dual-benefit pattern shown in animal models.
Advertisement
03 — Pharmacokinetics
Pharmacokinetics and Administration
How genistein moves through the body is the single biggest qualifier on everything above. It is absorbed but then heavily conjugated, so the free, active form in the bloodstream is a small fraction of the total — and that free level sits far below the concentrations active in the laboratory.
Absorption
Genistein is absorbed within a few hours but rapidly conjugated. After a purified oral dose, total plasma genistein peaks at 4–6 hours, but only about 1–4% circulates as the free, pharmacologically active aglycone.
The Concentration Gap
Laboratory effects need roughly 5–113 µM genistein, while the free aglycone achievable in human plasma sits near 0.07–0.17 µM — a gap of two to three orders of magnitude for the cytotoxic mechanisms.
Clinical Dose Context
Completed oncology trials used 30 mg/day (prostate) up to 450 mg/day (soy extract). No target exposure is defined, and even high doses keep the free level below the active laboratory range.
Formulation Effects
The one genistein formulation in clinical development — the nanosuspension BIO 300 — has now reached early-phase human oncology, given during chemoradiotherapy for lung cancer, but only in an uncontrolled safety study. No controlled trial has tested an enhanced form for tumor benefit.
Metabolism
Genistein undergoes rapid glucuronidation and sulfation; its conjugates are pumped out by the BCRP transporter, and glucuronides can be converted back to the active aglycone during enterohepatic recycling.
Co-Dosing Considerations
The strongest signal is with endocrine therapy — genistein negated tamoxifen and letrozole in animal models — alongside a laboratory BCRP-transporter signal of unproven clinical relevance. Decisions belong with the treating team.
Absorption
Genistein is a small, poorly water-soluble aglycone with low oral bioavailability, absorbed in the upper gut after gut enzymes hydrolyze its dietary glycoside (genistin) to the aglycone. In healthy volunteers given single ascending oral doses of purified synthetic genistein (30–300 mg), mean total-genistein peak concentration rose from about 0.9 to 6.7 µM at 4–6 hours, with an elimination half-life of 7.5–10.2 hours; exposure was dose-proportional across the range, but the peak concentration became sub-proportional at 300 mg, indicating absorption becomes rate-limited at the top dose.[6] The defining fact, though, is not the total but the free fraction — see The Concentration Gap and Metabolism.
The Concentration Gap
This is genistein's central limitation, and it has three parts. First, the free fraction: in cancer patients dosed with soy isoflavones, total plasma genistein reached 4.3–16.3 µM, but the free, unconjugated aglycone — the active species — was only 0.066–0.17 µM, roughly one to four percent of the total.[7] Second, concentration: the mechanisms above act in the tens of micromolar. Third, direction: at the low, achievable concentrations, genistein can act as an estrogen agonist and stimulate estrogen-receptor-positive tumor growth, only becoming antiproliferative above about 20 µM[41] — so the low end of the range is not simply a weaker version of the high-dose biology.
| Benchmark | Concentration | Interpretation |
|---|---|---|
| Free genistein in human plasma (active form) | ~0.07–0.17 µM | The pharmacologically active fraction after oral dosing — about 1–4% of total, the rest largely inactive conjugates[7] |
| Esophageal antiproliferative IC50 (lowest on page) | 5–15 µM | Tumor-selective across three esophageal lines (125 µM in normal cells), yet still roughly 30–200× the free plasma level[53] |
| Pancreatic STAT3-inhibition IC50 | 20–25 µM | Tumor-selective versus 120 µM in normal ductal cells, but well above achievable free exposure[20] |
| Colorectal ferroptosis IC50 | 108–113 µM | Among the highest effective concentrations — about three orders of magnitude above free plasma genistein[30] |
Clinical Dose Context
Dietary genistein intake in soy-consuming populations is in the tens of milligrams per day; supplements provide from about 30 mg (purified) to several hundred milligrams (soy-isoflavone concentrates). The completed oncology trials span this range, and none reached the concentrations active in cell studies as free genistein.
| Context | Dose | Result |
|---|---|---|
| Prostate RCT, pre-prostatectomy | 30 mg/day | Synthetic genistein; borderline PSA change (P=0.051), no tissue proliferation effect[2,3] |
| Prostate active surveillance | 450 mg/day | Aglycone-rich soy extract; no PSA change at 6 or 12 months[4] |
| Metastatic colorectal, with FOLFOX ± bevacizumab | Per-cycle | Safety/tolerability endpoint; uncontrolled, no efficacy claim[1] |
| Healthy-volunteer PK | 30–300 mg single | Total peak 0.9–6.7 µM; absorption rate-limited at the top dose[6] |
Formulation Effects
Genistein's poor solubility has driven enhanced-delivery research, and one formulation has genuine clinical development — but for a non-oncology indication. BIO 300 is a crystalline genistein nanosuspension developed as a radiation medical countermeasure; its protective data are in normal-tissue radioprotection (see Safety and the Protect pathways above).[36,37,58] BIO 300 has since reached early-phase human oncology: an open-label phase 1b/2a study gave oral BIO 300 (500–1,500 mg/day) to 21 patients with non-small-cell lung cancer during chemoradiotherapy, with no dose-limiting toxicity, no change to chemotherapy pharmacokinetics, and a dose-dependent fall in the fibrosis marker TGF-β1; because it was uncontrolled and single-arm, the tumor-response rate cannot be attributed to BIO 300.[61] So no controlled trial has yet tested an enhanced formulation for a tumor or normal-tissue-protection benefit, and a bioavailability advantage cannot be assumed to translate into an oncology outcome. Purified synthetic genistein aglycone, used in the prostate trial and the healthy-volunteer pharmacokinetics, is the best-characterized oral form.[2,6]
Metabolism
Genistein undergoes rapid, extensive phase-II conjugation — glucuronidation and sulfation in the intestinal wall and liver — so circulating genistein is dominated by conjugated metabolites rather than the free aglycone; in humans the free fraction is only about 1–4% of total.[7] Disposition work adds the mechanism: the efflux transporter BCRP (ABCG2) governs the distribution of genistein's phase-II conjugates, pumping them into the intestine and bile, and genistein glucuronides can be hydrolyzed back to the active aglycone (while sulfates remain stable) — a conjugation-and-recycling cycle that keeps systemic free-aglycone exposure low.[49] The biological activity of the circulating conjugates within tumor tissue is not established.
Co-Dosing Considerations
Genistein's most important interaction is not an enzyme or transporter effect but an endocrine one: in estrogen-receptor-positive breast-cancer models, dietary genistein negated the anti-tumor effect of tamoxifen and of the aromatase inhibitor letrozole. Alongside this sits a transporter interaction — genistein is a confirmed BCRP substrate whose conjugates are BCRP-handled — and a class-theoretical CYP concern that was not quantified for this profile.
Discuss whether to combine, separate, or avoid genistein and a medication with your treating oncology team or physician.
| Flag | Interaction |
|---|---|
| Avoid | Endocrine therapy for estrogen-receptor-positive breast cancer (tamoxifen, aromatase inhibitors). In ovariectomized-mouse models, dietary genistein negated tamoxifen's tumor-suppressing effect — most potently at low, dietary-relevant doses — and reversed letrozole's inhibition dose-dependently, acting directly through genistein rather than loss of drug responsiveness. This is preclinical and in-vivo, not a human clinical interaction, but for a patient on endocrine therapy it is a documented antagonism concern.[43,44,45] |
| Monitor | Oncology drugs cleared by the BCRP/ABCG2 efflux transporter. Genistein and its phase-II conjugates interact with BCRP transport biology in laboratory systems, but whether supplemental genistein produces a clinically relevant BCRP-mediated interaction in humans has not been shown.[49,50] |
| Monitor | Drugs cleared by CYP enzymes. Genistein is widely described as a CYP modulator, but no clean quantitative human inhibition constant was verified for this profile, so any CYP interaction is presented as class-theoretical rather than demonstrated; worth flagging to the treating team for narrow-therapeutic-index medicines. |
Advertisement
04 — Onset & Washout
Onset and Washout
Genistein's plasma clock and its effect timeline are two different things. Total genistein peaks in the blood within a few hours and declines over roughly a day, but whether that maps onto how long any biological effect lasts hasn't been measured — and the interaction of greatest concern is a hormone-signaling effect, not a plasma one.
Immediate Onset
Total genistein peaks in the blood a few hours after an oral dose and then declines over roughly a day — this describes plasma concentration only, not how long any biological effect lasts.
Steady State
Daily high-dose supplementation reaches a measurable steady-state total genistein, but steady-state levels of the free, active form aren't characterized — and a high total did not produce a PSA effect.
Accumulated Effect
The human trials dosed daily for weeks (before prostatectomy) to months (active surveillance); the cell and animal effects developed over sustained exposure, not a single dose.
Dosing Pattern in Studies
Most trials used continuous daily dosing; the metastatic-colorectal pilot used intermittent cycles — 7 days on, every 2 weeks. Those are the regimens that have been studied, not proof that any particular schedule has been tested against another.
Washout
How long genistein can remain a relevant factor for co-administered medications before it stops mattering.
No clinically validated washout period exists. Plasma genistein largely clears over about a day, but the interaction of greatest concern — antagonism of endocrine therapy — is a pharmacodynamic effect on tumor signaling, not a plasma-clearance phenomenon, so it can't be timed from genistein's half-life.
Two Distinct Clocks
Genistein's timeline splits into two genuinely different layers: how quickly it appears in and leaves the blood, and how long it takes for a tumor-relevant change to show up in a study. The two aren't connected by any measurement available here.
The plasma clock tracks genistein itself. After a single oral dose, total genistein peaks at 4–6 hours in healthy volunteers and is eliminated with a half-life of roughly 8–10 hours,[6] somewhat longer (15–22 hours) in cancer patients dosed with soy isoflavones, consistent with enterohepatic recycling of conjugates.[7] That describes plasma concentration only — not target engagement, tissue levels, or how long any downstream effect persists.
| Measured plasma exposure | Downstream phenotypic effect | |
|---|---|---|
| Onset | Fast — total plasma genistein peaks within 4 to 6 hours | Slow — the human trials measured outcomes over weeks (before surgery) to months (active surveillance) |
| Persistence | Short — plasma half-life roughly 8 to 22 hours; largely cleared over about a day | Sustained — trials dosed over weeks to months (daily in prostate and breast; 7-day cycles in metastatic colorectal), not single doses |
| What it covers | Measured plasma genistein only — dominated by largely inactive conjugates, not the free active form or tissue levels | The actual clinical readouts — PSA, tumor-tissue proliferation genes — recorded under the studied, repeated-dosing regimens |
The downstream clock is what the trials actually measured. Patients were dosed over weeks to months before any tumor-relevant endpoint was read — continuously in the prostate and breast trials, in 7-day cycles in the metastatic-colorectal pilot — and no study measured how plasma exposure connects to the outcome, only that sustained, repeated dosing is what the trials used.
Steady State and Accumulation
Chronic daily dosing does reach a measurable steady state — 450 mg/day produced serum genistein of about 40 µmol/L at 6 months.[4] But steady-state exposure of the free, active aglycone (a small fraction of that total) is not characterized, and the high steady-state total did not produce a PSA effect. A single dose does not represent steady-state tissue exposure.
Dosing Pattern in Studies
The prostate and breast oncology trials used continuous daily dosing (30–450 mg/day over weeks to months),[2,4] while the metastatic-colorectal pilot used an intermittent schedule — genistein for 7 days every 2 weeks, starting 4 days before each chemotherapy cycle;[1] animal studies used daily oral or intraperitoneal dosing over the experimental period.[15,28] This describes how genistein was studied, not a recommended regimen. No study compared schedules head-to-head or tied the plasma-exposure pattern to the downstream effect.
Washout
No clinically validated genistein washout period has been established. Plasma genistein largely clears over roughly a day,[6] but the interaction of greatest concern is not a clearance phenomenon: the antagonism of endocrine therapy is a pharmacodynamic effect on estrogen-receptor signaling in tumor tissue, which cannot be calculated from genistein's plasma half-life. A washout interval should not be inferred from clearance alone, and none is recommended here — any interaction concern should be raised with the treating team as soon as genistein is started, and the timing decision belongs to the reader's medical team.
Advertisement
05 — Safety
Safety Profile
Purified genistein has been well tolerated in the short human studies available, but two oncology-specific cautions dominate its safety profile: as a phytoestrogen it can stimulate estrogen-receptor-positive tumors and blunt anti-estrogen therapy, and its topoisomerase mechanism is genotoxic at high exposure. A thyroid-enzyme effect and sparse long-term data round out the picture.
Estrogen-receptor stimulation — at low, achievable concentrations genistein can stimulate estrogen-receptor-positive tumor growth and negate anti-estrogen therapy in animal models; not neutral in hormone-sensitive cancer.
Genotoxicity (topoisomerase-II) — genistein's topoisomerase-II poisoning causes DNA double-strand breaks and gene translocations of a type linked to leukaemia; a mechanistic, high-dose concern.
Thyroid-enzyme inhibition — genistein can inhibit thyroid peroxidase in the laboratory, but a three-year randomized trial found no effect on thyroid function; any residual concern centers on iodine-deficient people, since adequate iodide abolishes the enzyme effect.
Limited long-term data / pregnancy — short-term tolerability is good, but high-dose, long-term, and pregnancy safety are not well characterized; supplemental use in pregnancy is best reviewed by a clinician.
Adverse Effects in Human Trials
Purified genistein has been well tolerated in the human studies available: 30 mg/day for weeks in prostate-cancer patients produced few and mild adverse events with no effect on thyroid-stimulating hormone or sex hormones,[2] single ascending doses to 300 mg were well tolerated in healthy volunteers,[6] and adding genistein to chemotherapy in metastatic colorectal cancer did not raise the adverse-event rate.[1] No dedicated genistein or soy-isoflavone hepatotoxicity monograph was located in the literature reviewed, and no prominent drug-induced liver-injury signal appears in the trial data — this is stated as an absence in the sources reviewed, not a proven clean safety record, and it does not extend to high-dose or long-term supplemental use during cancer therapy, which has not been characterized.
Estrogen-Receptor Activity — the Counter-Signal
Genistein is the canonical dietary phytoestrogen, and its estrogenic activity is not benign in hormone-sensitive cancer. At low, dietary-relevant concentrations it behaved as an estrogen agonist: it stimulated estrogen-receptor-positive breast-cancer proliferation from about 10 nM, induced estrogen-responsive genes, and — as dietary genistein — enlarged estrogen-dependent tumors in ovariectomized mice, with growth reversing on withdrawal; only above about 20 µM did it become antiproliferative.[41,42] Because genistein's pharmacokinetics keep the achievable free level in exactly the low range where stimulation occurs, this is the direction that matters clinically. The strongest form of the caution is drug antagonism: dietary genistein negated the anti-tumor effect of tamoxifen — most potently at low doses — and of the aromatase inhibitor letrozole in estrogen-receptor-positive models.[43,44,45] This is preclinical and does not establish clinical harm, but genistein cannot be assumed neutral in estrogen-receptor-positive breast cancer. These findings concern pharmacological or supplemental genistein exposure and animal models; they should not be read as showing that ordinary dietary soy worsens human breast-cancer outcomes or interferes with tamoxifen — in a pooled cohort of 9,514 breast-cancer survivors, higher post-diagnosis dietary soy intake was associated with lower, not higher, recurrence.[63] A striking corollary: genistein's preferred estrogen-receptor-β activity also appears to drive its radioprotective benefit (see the Protect pathways above) — so hazard and benefit draw on the same estrogen-receptor pharmacology, even though the low-dose breast-stimulation hazard is thought to run largely through ERα rather than ERβ.
Genotoxicity — the Topoisomerase Double-Edge
Genistein's topoisomerase-II-poisoning activity, one of its anti-leukaemia mechanisms,[33] is also genotoxic: it induces topoisomerase-II-dependent DNA double-strand breaks and MLL-gene translocations of the type implicated in infant and therapy-related leukaemia.[34] This is a mechanistic, preclinical concern relevant to high-dose exposure, and it is the reason the topoisomerase mechanism is treated as exploratory rather than as a therapeutic pathway above.
Thyroid
Genistein (and the related isoflavone daidzein) inhibit thyroid peroxidase — the enzyme of thyroid-hormone synthesis — acting as alternate substrates and, in the presence of hydrogen peroxide, causing irreversible enzyme inactivation at concentrations (IC50 roughly 1–10 µM) near achievable plasma isoflavone levels.[47] That is a biochemical finding, and the human data are reassuring: a three-year randomized, placebo-controlled trial of 54 mg/day genistein aglycone found no effect on thyroid-stimulating hormone, free T3/T4 or thyroid autoantibodies,[48] and the prostate trial likewise found no change in thyroid-stimulating hormone at 30 mg/day.[2] Critically, adding iodide completely abolished the enzyme inactivation, so any residual concern is largely confined to iodine-deficient individuals or those with pre-existing thyroid disease.
Interactions and Pregnancy
Genistein's drug interactions are handled once under Co-Dosing Considerations in Pharmacokinetics and Administration above: the endocrine-therapy antagonism (the load-bearing one), a BCRP/ABCG2 transporter signal, and a class-theoretical CYP concern. Genistein is a normal dietary constituent, but its endocrine and thyroid-enzyme activity make dedicated high-dose-supplement use in pregnancy best reviewed by a clinician; dedicated high-dose pregnancy-safety data were not identified.
06 — Sourcing
Sourcing Guide
Genistein supplements come as either purified synthetic aglycone or a soy-isoflavone concentrate, and the two are not interchangeable — the purified aglycone is the best-characterized oral form, while concentrates carry a mix of isoflavones and their glycosides. Whatever the form, the pharmacokinetics above apply: only a small fraction reaches the bloodstream as free, active genistein. Brand quality, characterization, and how the label reports its isoflavone content all matter. Our Sourcing Guide offers a curated list of products available on the retail market chosen with those concerns in mind.
Genistein Sourcing Guide07 — Literature
References
Last reviewed: August 2026